The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
Open accessAbstract
PURPOSE: Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in patients with non–clear cell renal cell carcinoma (nccRCC). The phase II KEYNOTE-427 study (cohort B) was conducted to assess the efficacy and safety of single-agent pembrolizumab, a PD-1 inhibitor, in advanced nccRCC. METHODS: Patients with histologically confirmed, measurable (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) nccRCC and no prior systemic therapy received pembrolizumab 200 mg intravenously once every 3 weeks for ≤ 24 months. The primary end point was objective response rate (ORR) per RECIST v1.1. RESULTS: Among enrolled patients (N = 165), 71.5% had confirmed papillary, 12.7% had chromophobe, and 15.8% had unclassified RCC histology. Most patients (67.9%) had intermediate or poor International Metastatic RCC Database Consortium risk status and tumors with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 1 (61.8%). The median time from enrollment to database cutoff was 31.5 months (range, 22.7-38.8). In all patients, the ORR was 26.7%. The median duration of response was 29.0 months; 59.7% of responses lasted ≥ 12 months. The ORR by CPS ≥ 1 and CPS < 1 status was 35.3% and 12.1%, respectively. The ORR by histology was 28.8% for papillary, 9.5% for chromophobe, and 30.8% for unclassified. Overall, the median progression-free survival was 4.2 months (95% CI, 2.9 to 5.6); the 24-month rate was 18.6%. The median overall survival was 28.9 months (95% CI, 24.3 months to not reached); the 24-month rate was 58.4%. Overall, 69.7% of patients reported treatment-related adverse events, most commonly pruritus (20.0%) and hypothyroidism (14.5%). Two deaths were treatment related (pneumonitis and cardiac arrest). CONCLUSION: First-line pembrolizumab monotherapy showed promising antitumor activity in nccRCC. The safety profile was similar to that observed in other tumor types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Self-citationAvelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Self-citationon behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Self-citationHeng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M.-H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70559-4 · Cited by 1,030
Self-citationThe Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Ricketts, C. J., De Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.075 · Cited by 770
Self-citationThe Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Ricketts, C. J., De Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.032 · Cited by 734
Self-citationBaxi, S., Yang, A., Gennarelli, R. L., Khan, N., Wang, Z., Boyce, L., & Korenstein, D. (2018) · BMJ · doi:10.1136/bmj.k793 · Cited by 578
Motzer, R. J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M., & Reuter, V. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.123 · Cited by 496
Motzer, R. J., Agarwal, N., Beard, C., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S. L., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0043 · Cited by 470
Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00515-x · Cited by 426
Tannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Dubauskas Lim, Z., Tamboli, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 364
Self-citationPD-L1 expression in nonclear-cell renal cell carcinoma
Choueiri, T. K., Fay, A. P., Gray, K. P., Callea, M., Ho, T. H., Albiges, L., Bellmunt, J., Song, J., Carvo, I., Lampron, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu445 · Cited by 302
Self-citationCardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
Du, Z., Chen, W., Xia, Q., Shi, O., & Chen, Q. (2020) · Biomarker Research · doi:10.1186/s40364-020-00195-3 · Cited by 228
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Koshkin, V. S., Barata, P. C., Zhang, T., George, D. J., Atkins, M. B., Kelly, W. J., Vogelzang, N. J., Pal, S. K., Hsu, J., Appleman, L. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0319-9 · Cited by 185
Self-citationAtkins, M. B., Clark, J. I., & Quinn, D. I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx151 · Cited by 156
Self-citationMcGregor, B. A., McKay, R. R., Braun, D. A., Werner, L. L., Gray, K. P., Flaifel, A., Signoretti, S., Hirsch, M. S., Steinharter, J. A., Bakouny, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01882 · Cited by 147
Self-citationChahoud, J., Msaouel, P., Campbell, M. T., Bathala, T. K., Xiao, L., Gao, J., Zurita, A. J., Shah, A. Y., Jonasch, E. W., Sharma, P., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0372 · Cited by 91
Giorgi, U. D., Cartenì, G., Giannarelli, D., Basso, U., Galli, L., Cortesi, E., Caserta, C., Pignata, S., Sabbatini, R., Bearz, A., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14461 · Cited by 85
Wang, Z., Peng, S., Xie, H., Guo, L., Cai, Q., Shang, Z., Jiang, N., & Niu, Y. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0488-3 · Cited by 57
PD-L1 expression in papillary renal cell carcinoma
Motoshima, T., Komohara, Y., Ma, C., Dewi, A. K., Noguchi, H., Yamada, S., Nakayama, T., Kitada, S., Kawano, Y., Takahashi, W., et al. (2017) · BMC Urology · doi:10.1186/s12894-016-0195-x · Cited by 45
Systemic Therapy for Non–Clear Cell Renal Cell Carcinoma
Zhang, T., Gong, J., Maia, M. C., & Pal, S. K. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175572 · Cited by 40
Cui, P., Ma, J., Wang, F., Zhang, J., Tao, H., & Hu, Y. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s143939 · Cited by 20
Cited by
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y.-H., Hajek, J., Symeonides, S. N., Lee, J. L., Sarwar, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106391 · Cited by 785
Self-citationKidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., Derweesh, I. H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0001 · Cited by 667
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.05.537 · Cited by 369
Self-citationYoung, M., Jackson-Spence, F., Beltran, L., Day, E., Suarez, C., Bex, A., Powles, T., & Szabados, B. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00917-6 · Cited by 271
Self-citationDeterminants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Au, L., Hatipoglu, E., Robert de Massy, M., Litchfield, K., Beattie, G., Rowan, A., Schnidrig, D., Thompson, R., Byrne, F., Horswell, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.001 · Cited by 260
Metadata
- Authors
- McDermott, D. F., Lee, J.-L., Ziobro, M., Suarez, C., Langiewicz, P., Matveev, V. B., Wiechno, P., Gafanov, R. A., Tomczak, P., Pouliot, F., Donskov, F., Alekseev, B. Y., Shin, S. J., Bjarnason, G. A., Castellano, D., Silverman, R. K., Perini, R. F., Schloss, C., & Atkins, M. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-03-20
- Volume
- 39
- Issue
- 9
- Pages
- 1029-1039
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3126738486
- Cited by
- 291
- References
- 29
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.